BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant. 2004;4:1514-1522. [PMID: 15307840 DOI: 10.1111/j.1600-6143.2004.00539.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010;49:141-175. [PMID: 20170205 DOI: 10.2165/11317350-000000000-00000] [Cited by in Crossref: 234] [Cited by in F6Publishing: 190] [Article Influence: 21.3] [Reference Citation Analysis]
2 Gharbi C, Gueutin V, Izzedine H. Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs). Clin Kidney J 2014;7:115-20. [PMID: 25852858 DOI: 10.1093/ckj/sfu001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
3 Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, Bemelman FJ, de Fijter JW, Guchelaar HJ. Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. CPT Pharmacometrics Syst Pharmacol 2014;3:e100. [PMID: 24522145 DOI: 10.1038/psp.2013.78] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
4 Lemahieu WP, Maes BD, Vanrenterghem Y. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. Transplant Proc 2005;37:2051-3. [PMID: 15964336 DOI: 10.1016/j.transproceed.2005.03.095] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
5 Felipe CR, Park S, Pinheiro-machado PG, Garcia R, Casarini DE, Moreira S, Tedesco-silva Jr H, Medina-pestana JO. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. Fundamental & Clinical Pharmacology 2009;23:625-31. [DOI: 10.1111/j.1472-8206.2009.00699.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
6 Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int 2005;67:1152-60. [PMID: 15698457 DOI: 10.1111/j.1523-1755.2005.00182.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
7 Amariles P, Andrés Giraldo N, José Faus M. Interacciones medicamentosas: aproximación para establecer y evaluar su relevancia clínica. Medicina Clínica 2007;129:27-35. [DOI: 10.1157/13106681] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
8 Qureshi W, Mittal C, Ahmad U, Alirhayim Z, Hassan S, Qureshi S, Khalid F. Clinical predictors of post-liver transplant new-onset heart failure. Liver Transpl. 2013;19:701-710. [PMID: 23554120 DOI: 10.1002/lt.23654] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
9 Pfrepper C, Herber A, Weimann A, Siegemund R, Engelmann C, Aehling N, Seehofer D, Berg T, Petros S. Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation. Transpl Int 2021;34:423-35. [PMID: 33336411 DOI: 10.1111/tri.13804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 2006;62:485-91. [PMID: 16995870 DOI: 10.1111/j.1365-2125.2005.02519.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
11 Groth K, Brännström M, Mölne J, Wranning CA. Cyclosporine A exposure during pregnancy in mice: effects on reproductive performance in mothers and offspring. Hum Reprod 2010;25:697-704. [PMID: 20085916 DOI: 10.1093/humrep/dep470] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
12 Vanhove T, Spriet I, Annaert P, Maertens J, Van Cleemput J, Vos R, Kuypers D. Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. Ther Drug Monit. 2017;39:77-82. [PMID: 27861314 DOI: 10.1097/ftd.0000000000000356] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 6.3] [Reference Citation Analysis]
13 Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 2008;23:3111-9. [PMID: 18469305 DOI: 10.1093/ndt/gfn223] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
14 Wannhoff A, Weiss KH, Schemmer P, Stremmel W, Gotthardt DN. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation. 2014;98:e12-e13. [PMID: 25022236 DOI: 10.1097/tp.0000000000000223] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Samaniego M, Becker BN, Djamali A. Drug Insight: maintenance immunosuppression in kidney transplant recipients. Nat Rev Nephrol 2006;2:688-99. [DOI: 10.1038/ncpneph0343] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
16 Sieg A, Weeks P, Krustchinsky L, Rajapreyar I. Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter? Transplantation Reviews 2016;30:178-86. [DOI: 10.1016/j.trre.2016.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
17 Barau C, Blouin P, Creput C, Taburet A, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipients. Fundamental & Clinical Pharmacology 2009;23:423-5. [DOI: 10.1111/j.1472-8206.2009.00706.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
18 Santeusanio AD, Weinberg AD, Florman SS, Schiano TD. Safety of direct-acting oral anticoagulants relative to warfarin in a matched cohort of liver transplant recipients. Clin Transplant 2020;34:e13756. [PMID: 31738454 DOI: 10.1111/ctr.13756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Nogueira J, Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol 2007;2:766-85. [PMID: 17699494 DOI: 10.2215/CJN.04131206] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
20 Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, Fried L. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis. 2015;65:354-366. [PMID: 25465166 DOI: 10.1053/j.ajkd.2014.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 8.7] [Reference Citation Analysis]
21 Kropeit D, von Richter O, Stobernack HP, Rübsamen-Schaeff H, Zimmermann H. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. Clin Pharmacol Drug Dev 2018;7:9-21. [PMID: 28967706 DOI: 10.1002/cpdd.388] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
22 Bonhomme-Faivre L, Picard V, Saliba F, Abbara C, Fodil M, Chaunoy M, Farinotti R. Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am J Health Syst Pharm 2009;66:1645-51. [PMID: 19729569 DOI: 10.2146/ajhp080396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 Mahé E, Morelon E, Lechaton S, Kreis H, de Prost Y, Bodemer C. Angioedema in Renal Transplant Recipients on Sirolimus. Dermatology 2007;214:205-9. [DOI: 10.1159/000099584] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
24 Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Fernandes FB, Casarini DE, Tedesco-Silva H Jr, Medina-Pestana JO. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009;23:137-45. [PMID: 19267777 DOI: 10.1111/j.1472-8206.2008.00644.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
25 Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation. 2005;80:977-984. [PMID: 16249748 DOI: 10.1097/01.tp.0000174131.47469.d2] [Cited by in Crossref: 87] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
26 Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt H, Danhof M, de Fijter H, Guchelaar HJ. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol 2010;66:579-90. [PMID: 20354687 DOI: 10.1007/s00228-010-0810-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
27 Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opinion on Drug Metabolism & Toxicology 2020;16:59-78. [DOI: 10.1080/17425255.2020.1701653] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005;5:207-17. [PMID: 15643980 DOI: 10.1111/j.1600-6143.2005.00748.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
29 Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metabolism Reviews 2016;48:88-112. [DOI: 10.3109/03602532.2016.1151037] [Cited by in Crossref: 71] [Cited by in F6Publishing: 39] [Article Influence: 14.2] [Reference Citation Analysis]
30 Ong SC, Gaston RS. Thirty Years of Tacrolimus in Clinical Practice. Transplantation 2021;105:484-95. [PMID: 32541562 DOI: 10.1097/TP.0000000000003350] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 David-Neto E, Agena F, Ramos F, Triboni AHK, Romano P, de Almeida Rezende Ebner P, Coelho V, Galante NZ, Lemos FBC. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. Transplantation 2017;101:2133-8. [PMID: 27798513 DOI: 10.1097/TP.0000000000001549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
32 Lemahieu WPD, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus. Am J Transplant 2005;5:2236-43. [DOI: 10.1111/j.1600-6143.2005.01005.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 6.4] [Reference Citation Analysis]
33 Piao SG, Bae SK, Lim SW, Song J, Chung BH, Choi BS, Yang CW. Drug Interaction Between Cyclosporine and mTOR Inhibitors in Experimental Model of Chronic Cyclosporine Nephrotoxicity and Pancreatic Islet Dysfunction. Transplantation 2012;93:383-9. [DOI: 10.1097/tp.0b013e3182421604] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
34 Salerno DM, Tsapepas D, Papachristos A, Chang JH, Martin S, Hardy MA, McKeen J. Direct oral anticoagulant considerations in solid organ transplantation: A review. Clin Transplant. 2017;31. [PMID: 27859621 DOI: 10.1111/ctr.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
35 Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases. Nephrology Dialysis Transplantation 2006;21:197-202. [DOI: 10.1093/ndt/gfi113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
36 Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, Russmann S, Corti N, Wüthrich RP. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008;8:803-10. [PMID: 18318784 DOI: 10.1111/j.1600-6143.2007.02136.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
37 Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opinion on Drug Metabolism & Toxicology 2008;4:923-39. [DOI: 10.1517/17425255.4.7.923] [Cited by in Crossref: 130] [Cited by in F6Publishing: 94] [Article Influence: 10.0] [Reference Citation Analysis]
38 Tafazoli A. Cyclosporine use in hematopoietic stem cell transplantation: pharmacokinetic approach. Immunotherapy 2015;7:811-36. [DOI: 10.2217/imt.15.47] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, Duclos-Vallée JC, Taburet AM, Samuel D, Vittecoq D. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007;46:941-52. [PMID: 17922559 DOI: 10.2165/00003088-200746110-00002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
40 Oswald S, Terhaag B, Siegmund W. In Vivo Probes of Drug Transport: Commonly Used Probe Drugs to Assess Function of Intestinal P-glycoprotein (ABCB1) in Humans. In: Fromm MF, Kim RB, editors. Drug Transporters. Berlin: Springer Berlin Heidelberg; 2011. pp. 403-47. [DOI: 10.1007/978-3-642-14541-4_11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
41 Gaston RS, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Halloran P, Hunsicker L, Rush D, Matas AJ. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009;9:1811-5. [PMID: 19519808 DOI: 10.1111/j.1600-6143.2009.02696.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
42 Khan E, Killackey M, Kumbala D, LaGuardia H, Liu YJ, Qin HZ, Alper B, Paramesh A, Buell J, Zhang R. Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World J Nephrol. 2014;3:107-113. [PMID: 25332902 DOI: 10.5527/wjn.v3.i3.107] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
43 Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol. 2019;12:781-790. [PMID: 31242782 DOI: 10.1080/17512433.2019.1637733] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MP, van Zuilen AD. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. Transplantation. 2013;95:397-402. [PMID: 23250333 DOI: 10.1097/tp.0b013e3182734651] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
45 Rizk J, Mehra MR. Anticoagulation management strategies in heart transplantation. Prog Cardiovasc Dis 2020;63:210-8. [PMID: 32035125 DOI: 10.1016/j.pcad.2020.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
46 de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplantation Reviews 2008;22:6-20. [DOI: 10.1016/j.trre.2007.09.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
47 Srinivas NR. Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data: Cyclosporine AUC Prediction with a Single Time Point. Biopharm Drug Dispos 2015;36:575-86. [DOI: 10.1002/bdd.1967] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Bourlière M, Charles Duclos-vallée J, Pol S. Foie et antirétroviraux : hépatotoxicité, stéatose et monitoring en cas d’hépatopathie. Gastroentérologie Clinique et Biologique 2007;31:895-905. [DOI: 10.1016/s0399-8320(07)73987-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
49 Li X, Hou X, Ding W, Cong S, Zhang Y, Chen M, Meng Y, Lei J, Liu Y, Li G. Sirolimus-loaded polymeric micelles with honokiol for oral delivery. Journal of Pharmacy and Pharmacology 2015;67:1663-72. [DOI: 10.1111/jphp.12482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]